Valuation: Standard BioTools Inc.

Market Cap 280M 242M 227M 206M 388M 26.74B 395M 2.66B 1.04B 13.39B 1.05B 1.03B 44.5B P/E 2026 *
-7.12x
P/E 2027 * -4.45x
Enterprise Value 280M 242M 227M 206M 388M 26.74B 395M 2.66B 1.04B 13.39B 1.05B 1.03B 44.5B EV / Sales 2026 *
3.39x
EV / Sales 2027 * 3.41x
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Standard BioTools Inc.

1 day-4.99%
1 week-10.95%
Current month-17.93%
1 month-16.92%
3 months-27.66%
6 months-36.39%
Current year-44.34%
1 week 0.7
Extreme 0.705
0.81
1 month 0.7
Extreme 0.705
0.92
Current year 0.7
Extreme 0.7029
1.67
1 year 0.7
Extreme 0.7029
1.72
3 years 0.7
Extreme 0.7029
3.16
5 years 0.7
Extreme 0.7029
7.31
10 years 0.7
Extreme 0.7029
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 2024-08-31
Chief Executive Officer 63 2021-09-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 2022-03-31
Director/Board Member 53 2022-04-03
Director/Board Member 63 2021-09-30
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Tax

Chief Executive Officer

-362,625 0.0926%
7/23/26 Tax

Founder

-202,476 0.0519%
6/18/26 Free

Director

275,039 0.0705%
Change 5-day change 1-year change 3-year change Capi.($)
-4.99%-10.95%-42.08%-75.00% 280M
-1.28%-0.96%+20.30%+11.24% 218B
-0.71%-1.13%-4.02%-19.91% 142B
-1.68%+4.14%-17.85%+31.80% 139B
+0.27%+5.11%-49.76%+0.72% 75.11B
-1.04%+2.10%+17.05%+16.26% 52.8B
-0.60%-0.15%-17.19%-15.14% 50.66B
-0.51%+1.75%+24.61%+22.39% 41.95B
-0.32%+1.31%+41.37%+49.96% 40.49B
-0.14%+2.68%+0.40%+4.27% 33.28B
Average -1.01%+0.35%-2.72%+2.66% 79.38B
Weighted average by Cap. -0.67%+1.12%+0.45%+9.16%

Financials

2026 *2027 *
Net sales 82.5M 71.26M 66.96M 60.89M 114M 7.89B 116M 785M 307M 3.95B 310M 303M 13.13B 82.1M 70.91M 66.63M 60.6M 114M 7.85B 116M 781M 305M 3.93B 308M 302M 13.06B
Net income -38.8M -33.51M -31.49M -28.64M -53.84M -3.71B -54.73M -369M -144M -1.86B -146M -143M -6.17B -62.9M -54.33M -51.05M -46.43M -87.29M -6.01B -88.73M -598M -234M -3.01B -236M -231M -10.01B
Net Debt - -
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
26-08-14 US$0.7124 -4.99% 1,305,384
26-08-13 US$0.7498 -5.58% 1,295,792
26-08-12 US$0.7941 +0.84% 1,037,399
26-08-11 US$0.7875 -0.16% 450,216
26-08-10 US$0.7888 -1.40% 757,334
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.7124USD
Average target price
1.350USD
Spread / Average Target
+89.50%

Quarterly revenue - Rate of surprise